JOHN P. UTZ, M.D.; ALBERT TREGER, M.D.
Thirty years ago this June, Fleming1 first reported the antibacterial action of cultures of Penicillium, thus in one sense inaugurating the Antibiotic Era. During this period many antibiotics have been developed and used successfully in treating bacterial diseases. However, only two mycoses, actinomycosis and nocardiosis, have responded to any of these antibacterial drugs. In the four years since a symposium on the therapy of systemic fungal infections,2 a number of new and promising antifungal drugs have been developed, and one of these, amphotericin, has been given clinical trials in a large number of patients. These considerations have prompted this present
UTZ JP, TREGER A. THE CURRENT STATUS OF CHEMOTHERAPY OF SYSTEMIC FUNGAL DISEASE(THE CURRENT STATUS OF CHEMOTHERAPY OF SYSTEMIC FUNGAL DISEASE*). Ann Intern Med. 1959;51:1220–1229. doi: 10.7326/0003-4819-51-6-1220
Download citation file:
Published: Ann Intern Med. 1959;51(6):1220-1229.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use